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Abstract 
Multiple myeloma (MM) is a malignant plas-
ma  cell  disease.  Several  proinflammatory
cytokines produced by malignant plasma cells
and  bone  marrow  (BM)  stromal  cells  are
involved in the pathogenesis of the disease. We
evaluated serum levels of the proinflammatory
cytokines Interleukin-1β (IL-1β), Interleukin-6
(IL-6), Interleukin-8 (IL-8), macrophage inflam-
matory protein-1α (MIP-1α), in MM patients
before  treatment,  and  determined  its  signifi-
cance in tumor progression. We also analyzed
the correlation between measured parameters
with proliferating cell nuclear antigen (PCNA).
Forty-four MM patients and 20 healthy controls
were studied. Serum levels of the proinflamma-
tory cytokines were measured using enzyme-
linked immunosorbent assay (ELISA), whereas
PCNA  value  in  the  BM  was  determined  by
immunohistochemistry  staining.  The  mean
concentrations of the measured cytokines were
significantly different among the three stages of
disease, with higher values in advanced disease
stage. Furthermore, patients with MM had sig-
nificantly higher serum levels of the measured
cytokines than in controls. A positive correlation
was found between IL-6 with IL-1β, IL-8 and
MIP-1α. Similarly, IL-8 and MIP-1α were posi-
tively correlated with markers of disease activi-
ty such as β2 microglobulin and LDH. The pro-
liferation  index,  determined  by  PCNA
immunostaining, was higher in advanced dis-
ease stage. Furthermore PCNA value correlated
significantly with β2 microglobulin, LDH and
the  levels  of  the  measured  cytokines.  Our
results showed that the proliferative activity, as
measured with PCNA, increases in parallel with
disease stage. The positive correlation between
PCNA and other measured mediators supports
the involvement of these factors in the biology
of  myeloma  cell  growth  and  can  be  used  as
markers of disease activity and as possible ther-
apeutic targets.
Introduction
Multiple myeloma (MM) is characterized by
the slow proliferation of malignant plasma cells.
Various  cytokines  control  growth,  progression
and dissemination of the disease.1 Interleukin 6
(IL-6) has been recognized as the major human
myeloma cell growth factor in vitro and induces
the  differentiation  of  B-cells  to  plasma  cells,
which produce monoclonal antibodies and acute-
phase proteins.2 Several nuclear proteins have
been described as proliferative markers in nor-
mal, neoplastic and transformed cells.3 Plasma
cell nuclear antigen (PCNA) well correlates with
cellular  proliferation  in  benign  and  malignant
neoplasms, including haematological malignan-
cies;4,5 its level of expression varies during the
cell cycle, suggesting that under certain condi-
tions PCNA is a marker of S-phase cells.6
The  role  of  interleukin  1β (IL-1β)  in  the
pathogenesis  of  MM  remains  controversial.
Several studies found elevated levels of IL-1β
in MM patients, suggesting that MM cells pro-
duce IL-1β.7 IL-1β is a potent inducer of IL-6
production in stromal cells and monocytes8and
has  an  important  role  of  IL-1β in  myeloma
bone  disease.9 Interleukin  8  (IL-8)  is  a
chemokine that targets neutrophils and lym-
phocytes.  Stromal  cells,  co-cultured  with
supernatants  from  bone  marrow  cells  of
patients with active myeloma, produce elevat-
ed amounts of IL-8.10 IL-8 plays a significant
role  in  inflammatory  and  tumor  associated
angiogenesis and tumor progression.11
Macrophage inflammatory protein-1α (MIP-
1α) is a chemokine that stimulates phagocyte
activity,12 and belongs to the RANTES family of
chemokines, which act as chemoattractant and
activators of monocytes.13 MIP-1α interaction
with  CCR2  receptors  activates  secretion  of
numerous  proinflammatory  signals.14
Furthermore, MIP-1α secreted from bone mar-
row  cells  of  MM  patients  stimulates  bone
absorption.15,16 The aims of the present study
were  to  measure  circulating  levels  of  proin-
flammatory cytokines, such as IL-1β, IL-6, IL-8,
MIP-1α, as well as LDH and β2 microglobulin,
which were identified as strong and independ-
ent prognostic factors in multiple myeloma17-19
and to discuss its significance in tumor pro-
gression. Additionally, we analyzed the correla-
tion of measured mediators with the prolifera-




Forty-four patients with MM (24 male and 20
female, mean age 66±10.2 years) were enrolled
in the study. Blood samples were obtained from
all patients at diagnosis and none of them had
recent  apparent  infections  or  had  received
treatment with cytostatic drugs in the past. The
frequencies of M-protein isotypes were 61.8%
IgG,  29.4%  IgA  and  8.8%  light  chain  only.
According to the criteria of Durie and Salmon’s
myeloma staging system,20at the time of serum
collection, 12 patients had stage I, 14 had stage
II and 18 had stage III. Biopsies were taken
from the posterior iliac crests using a manual
trephine. Twenty age-matched healthy volun-
teers  (8  female  and  12  male,  mean  age
64.4±12.1 years) were used as controls.
Methods
All blood samples were taken after informed
consent was given and were stored at -70°C.
Solid-phase sandwich enzyme-linked immuno  -
sorbent assay (ELISA) with monoclonal human
antiIL-6,  antiIL-1β,  antiIL-8,  and  antiMIP-1α
antibodies  from  commercially  available  kits
(Quantikine®,  R&D  Systems,  Inc.,
Minneapolis, MN, USA) was used to measure
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the  above  cytokines.  An  immunostaining
method was used to detect PCNA. The biopsies
were fixed in 10% neutral formalin for at least
24 h, and decalcified in 10% EDTA for 48 h, and
then  embedded  in  Paramat  extra  (BDH
Laboratory  Supplies,  Pool,  UK).  Initially,
Hematoxylin-Eosin (H&E) stained 3 μm-thick
section  from  each  Paramat-embedded  bone
marrow  biopsy  was  double-immunostained
with antibodies to PCNA (M 0879, DK-2600,
Dako, Glostrup, Denmark) and CD38 (M 7077,
DK-2600, Dako), using the DAKO Envision sys-
tem (En Vision HRP-conjugated polymer, Kit
5007, Dako).21
Statistical analysis
Mean values were expressed as mean±SD.
Statistical analysis was performed using one
analysis of variance (ANOVA) to test the exis-
tence of differences between different stages.
A post-hoc multiple comparisons test, Student-
Newman-Keuls  (SNK)  was  carried  out  to
determine  differences  between  means.
Statistical comparison between MM group and
control  group  was  made  using  the  nonpara-
metric Mann-Whitney test. Correlations were
assessed using the Spearman correlation coef-
ficient. Multiple logistic regressions analysis
with forward selection was applied to estimate
the risk (in the form of odd’s ratios) of having
multiple myeloma based on hematological and
histological parameters. A P value of <0.05 was
considered statistically significant.
Results
The mean concentrations of the measured
cytokines in the entire group of patients are
shown  in  Table  1.  All  the  above  measured
parameters were significantly different among
the three stages of disease, with higher values
in advancing disease stage (Table 1 and Figure
1). Furthermore, serum levels of IL-6, IL-1β, IL-
8  and  MIP-1α were  significantly  higher  in
patients with MM compared to controls. A pos-
itive correlation was found between IL-6 with
IL-1β (r=0.462,  P<0.002),  IL-8  (r=0.358,
P<0.01)  and  MIP-1α (r=0.380,  P<0.001).
Similarly, IL-8 and MIP-1α were positively cor-
related with factors of disease activity such as
β2 microglobulin (r=0.502, P<0.001; r=0.413,
P<0.005,  respectively)  and  LDH  (r=0.415,
P<0.006; r=0.475, P<0.001, respectively). The
mean PCNA values are shown in Table 1. PCNA
expression  was  higher  in  advanced  disease
stage  (Table  1  and  Figure  2).  Furthermore,
PCNA expression correlated significantly with
parameters  of  disease  activity  such  as  β2
microglobulun  and  LDH  (r=0.406,  P<0.006;
r=0.581,  P<0.0001,  respectively).  Similarly,
PCNA  value  correlated  with  the  measured
cytokines IL-6, IL-1β (results not shown graph-
ically), IL-8 (Figure 3) and MIP-1α (Figure 4)
(r=0.520,  P<0.0001;  r=0.545,  P<0.0001;
r=0.320, P<0.03 and r=0.383, P<0.01, respec-
tively).
The multivariate analysis showed that IL-1β
and β2 microglobulin are independent prog-
nostic factors (7.89 95% CI: 1.75-35.66 for IL-
1β and  7.47  95%  CI:  1.66-33.65  for  β2
microglobulin).
Discussion
The data presented in this study show that
serum concentrations of IL-6, IL-8, IL-1β MIP-
1α, LDH and β2 microglobulin in patients with
MM are significantly higher than normal con-
trols. Furthermore, these parameters are posi-
tively correlated with advancing disease stage.
We  also  found  a  significant  correlation
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Table 1. Measured parameters (Means±SD) for controls and multiple myeloma patients
according to disease stage.
Controls MM patients Stage I Stage II Stage III
B2M (mg/L) 1.2±0.5a 3.1±0.7 2.0±0.6 2.5±0.8 4.2±2.0b
LDH (U/mL) 176.2±27.3a 284.0±103.1 200.4±38.7 258.8±51.7 349±113.7c
IL-1￿ (pg/mL) 0.7±0.5a 2.8±1.3 1.5±0.6 2.8±1.0 3.7±1.0b
PCNA (%) 2.0±1.7a 26.8±24.7 6.6±5.2 24.0±12.4 41.4±29.0b
IL-8 (pg/mL) 27.6±5.8a 39.3±15.6 28.6±18.1 37.4±12.2 47.3±18.1b
MIP-1￿ (pg/mL) 22.4±4.2a 51.7±34.9 33.9±21.7 39.4±20.5 71.4±40.2d
IL-6 (pg/mL) 0.9±0.4a 6.2±5.9 1.8±0.4 3.6±1.8 10.9±6.4b
MM, multiple myeloma; aMM group vscontrol group, P<0.001 (Mann-Whitney test); bamong disease stages, P<0.001; camong disease
stages, P<0.02; dbetween stages I and II, P=0.896 and between stages I and III, P<0.001.
Figure 3. Correlation of proliferating cell
nuclear antigen with IL-8.
Figure 4. Correlation of proliferating cell
nuclear antigen with MIP-1α.
Figure 1. Levels of MIP-1α in controls and
the  three  stages  of  multiple  myeloma.
Among stages (P<0.001), between controls
and multiple myeloma patients (P<0.001).
Figure 2. Proliferating cell nuclear antigen
values in controls and the three stages of
multiple  myeloma.  Among  stages
(P<0.001), between controls and multiple
myeloma patients (P<0.001).[European Journal of Histochemistry 2011; 55:e21] [page 115]
between serum IL-6 and disease stage, sug-
gesting that IL-6 is a central growth and sur-
vival factor for MM cells.22 IL-1β is a proinflam-
matory cytokine stimulating IL-6 and IL-8 pro-
duction  in  the  stromal  cells  and  has  been
implicated in inflammatory and malignant dis-
orders.8,23 Although IL-1β is the major osteo-
clast  stimulating  factor  in  MM,  a  previous
report13 failed  to  confirm  the  role  for  this
cytokine in the pathogenesis of myeloma bone
disease. Our results showed that serum levels
of  IL-1β were  significantly  increased  with
advanced of disease stage and correlated sig-
nificantly with factors of disease activity, such
as LDH and β2 microglobulin, in patients with
normal renal function. Additionally IL-1β could
be  an  independent  prognostic  factor  as  our
results showed.
IL-8 plays a significant role in inflammation
and tumor associated angiogenesis24,25 and has
been found to significantly increase microvas-
cular density in several systems. Furthermore,
IL-8 is a chemotactic and growth factor in sev-
eral tumors.26,27 We found a significantly high-
er serum concentration of IL-8 in MM patients
at diagnosis compared to controls. Serum IL-8
was significantly correlated with MM stage and
disease activity. It was previously demonstrat-
ed that IL-8 stimulates the proliferation and
migration of MM cells.28
We also found that PCNA value increased
with advancing disease stage and correlated
significantly with prognostic factors, such as
IL-6, β2 microglobulin and LDH. Another inter-
esting observation of our study was the strong
correlation between PCNA and serum levels of
MIP-1α,  an  important  mediator  of  the  bone
destruction in patients with MM. The correla-
tion of MIP-1α with advanced disease stage
and  the  other  measured  cytokines,  suggests
that there is an important role of MIP-1α in
the  biology  of  myeloma,  which  can  be
explained by its impact on plasma cell prolifer-
ation and growth.18
In conclusion, our results showed that the
proliferative  activity  increases  with  disease
stage. The positive correlation between PCNA
and  other  measured  mediators  supports  the
involvement of these factors in the biology of
myeloma cell growth and can be used as mark-
ers of disease activity and as possible thera-
peutic targets.
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